Our analysis also shows frequent mutations and amplifications of FGFR2 in TCGA LUSC (lung squamous cell carcinoma) and UCEC (uterine corpus endometrial carcinoma) cohorts, as well as frequent mutations and amplifications of FGFR3 in BLCA (bladder urothelial carcinoma), HNSC (head and neck squamous cell carcinoma) and LUSC (lung squamous cell carcinoma) cohorts. This evidence concerns the gene FGFR3 and uterine corpus endometrial carcinoma.